$HTBX News

Last published 4y ago

4y agoHTBX NHWKNightHawk Biosciences to Present at the 4th Annual Treg Directed Therapies Summit on PTX-35GlobeNewswireDURHAM, N.C., May 10, 2022 (GLOBE NEWSWIRE) -- NightHawk Biosciences (NYSE:NHWK), a fully integrated biopharmaceutical company focused on developing first-in-class therapies to modulate the immune system, today announced that Matthew Seavey, Ph.D., MBA
4y agoHTBX NHWKHeat Biologics Completes Name Change to NightHawk Biosciences; Trading to Commence Under "NHWK" Effective at the Market Open TodayGlobeNewswireDURHAM, N.C., May 03, 2022 (GLOBE NEWSWIRE) -- Heat Biologics, Inc. / NightHawk Biosciences (NYSE American: HTBX; NHWK), a fully integrated biopharmaceutical company focused on developing first-in-class therapies to modulate the immune system, today an
4y agoHTBXHeat Biologics (NightHawk Biosciences) Announces that its Elusys Therapeutics Subsidiary has Executed a Contract to Deliver ANTHIM® to the Canadian GovernmentGlobeNewswireDURHAM, N.C., April 27, 2022 (GLOBE NEWSWIRE) -- Heat Biologics, Inc. (NYSE American: HTBX) (to be renamed "NightHawk Biosciences"), a fully integrated biopharmaceutical company focused on developing first-in-class therapies to modulate the immune syst
4y agoHTBXHeat Biologics ("NightHawk Biosciences") Completes Acquisition of Elusys TherapeuticsGlobeNewswireElusys becomes wholly-owned biodefense subsidiary of NightHawk Plans to expand ANTHIM® distribution abroad DURHAM, N.C., April 20, 2022 (GLOBE NEWSWIRE) -- Heat Biologics, Inc. (NYSE American: HTBX) (to be renamed "NightHawk Biosciences"), a ful
4y agoHTBXHeat Biologics Announces Planned Name Change to NightHawk Biosciences, Reflecting Company's Evolution, Therapeutic Pipeline Expansion, Vertical Integration and New Biodefense CapabilitiesGlobeNewswireDURHAM, N.C., April 19, 2022 (GLOBE NEWSWIRE) -- Heat Biologics, Inc. ("Heat") (NYSE American: HTBX), a clinical-stage biopharmaceutical company focused on developing novel biodefense assets and first-in-class therapies to modulate the immune system, t
4y agoHTBXREMINDER: Heat Biologics to Host Planned Investor and Media Livestream Event on Tuesday, April 19th at 10:30 AM ET to Discuss Latest DevelopmentsGlobeNewswireDURHAM, N.C., April 18, 2022 (GLOBE NEWSWIRE) -- Heat Biologics, Inc. ("Heat") (NYSE American: HTBX), a clinical-stage biopharmaceutical company focused on developing first-in-class therapies to modulate the immune system and novel biodefense assets, r
4y agoHTBXHeat Biologics' Scorpion Subsidiary Announces Planned Development of New Kansas Commercial/Biodefense Biomanufacturing FacilityGlobeNewswire500,000+ square foot facility to support commercial-scale biomanufacturing Livestreaming ceremony with Governor Laura Kelly Live from Manhattan, Kansas today at 11:00am ET/ 10:00am CT today at https://www.kansascommerce.gov/projectannouncement-4-18
4y agoHTBXHeat Biologics' Announces Planned Investor and Media Livestream Event to Discuss Latest DevelopmentsGlobeNewswireDURHAM, N.C., April 14, 2022 (GLOBE NEWSWIRE) -- Heat Biologics, Inc. ("Heat") (NYSE American: HTBX), a clinical-stage biopharmaceutical company focused on developing first-in-class therapies to modulate the immune system and novel biodefense assets, t
4y agoHTBXHeat Biologics Unveils Enhanced Allogeneic Cell Manufacturing ProcessGlobeNewswireDURHAM, N.C., March 25, 2022 (GLOBE NEWSWIRE) -- Heat Biologics, Inc. ("Heat") (NYSE American: HTBX), a clinical-stage biopharmaceutical company focused on developing novel biodefense assets and first-in-class therapies to modulate the immune system, t
4y agoHTBXHeat Biologics Announces Appointment of Greg Burel, Former Director of the Strategic National Stockpile, to its Biothreat Advisory Board and as Senior Advisor to the CompanyGlobeNewswireDURHAM, N.C., March 23, 2022 (GLOBE NEWSWIRE) -- Heat Biologics, Inc. ("Heat") (NYSE American: HTBX), a clinical-stage biopharmaceutical company focused on developing novel biodefense assets and first-in-class therapies to modulate the immune system, a
4y agoHTBXHeat Biologics Provides Year-End 2021 Business UpdateGlobeNewswireDURHAM, N.C., March 14, 2022 (GLOBE NEWSWIRE) -- Heat Biologics, Inc. ("Heat") (NYSE American: HTBX), a clinical-stage biopharmaceutical company focused on developing first-in-class therapies to modulate the immune system, today provided strategic, fin
4y agoHTBXHeat Biologics Announces Planned Transfer to the NYSE AmericanGlobeNewswireDURHAM, N.C., Feb. 02, 2022 (GLOBE NEWSWIRE) -- Heat Biologics, Inc. ("Heat") (NASDAQ:HTBX), a clinical-stage biopharmaceutical company focused on developing first-in-class therapies to modulate the immune system, announced today that it plans to chan
4y agoHTBXElusys Therapeutics Finalizes HHS Contract to Deliver ANTHIM®, Its Treatment for Inhalation Anthrax, to the U.S. Department of Health and Human ServicesGlobeNewswireCompleted first phase of contract for $50 million; HHS options to procure up to $31 million of ANTHIM by the first half of 2023 Reaffirms ANTHIM as an important medical countermeasure in the U.S. government's strategy to maintain sufficient quantiti
4y agoHTBXHeat Biologics Announces New PTX-35 Preclinical Data in Organ Transplantation and Provides Update on HS-110GlobeNewswireDURHAM, N.C., Jan. 12, 2022 (GLOBE NEWSWIRE) -- Heat Biologics, Inc. ("Heat") (NASDAQ: HTBX), a clinical-stage biopharmaceutical company focused on developing first-in-class therapies to modulate the immune system, today announced promising new preclin
4y agoHTBXHeat Biologics Announces Planned Acquisition of Elusys TherapeuticsGlobeNewswireDURHAM, N.C., Dec. 21, 2021 (GLOBE NEWSWIRE) -- Heat Biologics, Inc. ("Heat") (NASDAQ: HTBX), a clinical-stage biopharmaceutical company focused on developing first-in-class therapies to modulate the immune system, today announced it has executed a def
4y agoHTBXHeat Biologics Unveils RapidVax®, A Novel Cellular Vaccine Platform Targeting Known and Unknown Emerging Biological ThreatsGlobeNewswireDesigned for rapid "plug and play" programming and stockpiling against emerging infectious agents and viral mutations Emergence of Omicron and other COVID-19 variants underscores the need for a rapid, safe, and effective response to potential biolog
5y agoHTBXHeat Biologics Provides Third Quarter 2021 Business UpdateGlobeNewswireDURHAM, N.C., Nov. 10, 2021 (GLOBE NEWSWIRE) -- Heat Biologics, Inc. ("Heat") (NASDAQ: HTBX), today provided strategic, financial, and operational updates for the third quarter ended September 30, 2021. Jeff Wolf, Chief Executive Officer of Heat, co
5y agoHTBXHeat Biologics Appoints Paul Tebbey as Senior Vice President of Product Development and Portfolio StrategyGlobeNewswireDURHAM, N.C., Oct. 06, 2021 (GLOBE NEWSWIRE) -- Heat Biologics, Inc. ("Heat") (NASDAQ: HTBX), a clinical-stage biopharmaceutical company focused on developing first-in-class therapies to modulate the immune system, today announced the appointment of Pa
5y agoHTBXHeat Biologics CEO to Present at the Cantor Fitzgerald Global Healthcare Conference on September 29thGlobeNewswireDURHAM, N.C., Sept. 15, 2021 (GLOBE NEWSWIRE) -- Heat Biologics, Inc. (NASDAQ:HTBX), a clinical-stage biopharmaceutical company focused on developing first-in-class therapies to modulate the immune system, today announced that Jeff Wolf, Chief Executiv
5y agoHTBXHeat Biologics to Present at the H.C. Wainwright 23rd Annual Global Investment ConferenceGlobeNewswireDURHAM, N.C., Sept. 09, 2021 (GLOBE NEWSWIRE) -- Heat Biologics, Inc. (NASDAQ:HTBX), a clinical-stage biopharmaceutical company focused on developing first-in-class therapies to modulate the immune system, today announced that Jeff Wolf, Chief Executiv
5y agoHTBXHeat Biologics to Provide Corporate UpdateGlobeNewswireDURHAM, N.C., Aug. 30, 2021 (GLOBE NEWSWIRE) -- Heat Biologics, Inc. ("Heat") (NASDAQ: HTBX), a clinical-stage biopharmaceutical company focused on developing first-in-class therapies to modulate the immune system, today announced CEO Jeff Wolf will ho
5y agoHTBXIndustrial Heat, LLC - Appeal, AffirmedUS Patent Trial and Appeal Board
5y agoHTBXHeat Biologics Unveils Skunkworx Bio, New Drug Discovery SubsidiaryGlobeNewswireDURHAM, N.C., Aug. 26, 2021 (GLOBE NEWSWIRE) -- Heat Biologics, Inc. ("Heat") (NASDAQ: HTBX), a clinical-stage biopharmaceutical company focused on developing first-in-class therapies to modulate the immune system, today announced the launch of its who
5y agoHTBXHeat Biologics Announces Addition of Former US Senator Mark Pryor to Biothreat Advisory BoardGlobeNewswireDURHAM, N.C., Aug. 23, 2021 (GLOBE NEWSWIRE) -- Heat Biologics, Inc. ("Heat") (NASDAQ: HTBX), a clinical-stage biopharmaceutical company focused on developing first-in-class therapies to modulate the immune system, announces the addition of Mark Pryor,
5y agoHTBXHeat Biologics Announces New Additions to Biothreat Advisory BoardGlobeNewswireFormer Assistant Secretary of Defense for Nuclear, Chemical & Biological Defense Programs, Andrew C. Weber Expert on Chemical and Biological Weapons, Dr. Gregory Koblentz DURHAM, N.C., Aug. 19, 2021 (GLOBE NEWSWIRE) -- Heat Biologics, Inc. ("Hea
5y agoHTBXHeat Biologics Announces Formation of Biothreat Advisory BoardGlobeNewswireDURHAM, N.C., Aug. 18, 2021 (GLOBE NEWSWIRE) -- Heat Biologics, Inc. ("Heat") (NASDAQ: HTBX), a clinical-stage biopharmaceutical company focused on developing first-in-class therapies to modulate the immune system, announces it has commenced developmen
5y agoHTBXHeat Biologics Provides Second Quarter 2021 Business UpdateGlobeNewswireDURHAM, N.C., Aug. 11, 2021 (GLOBE NEWSWIRE) -- Heat Biologics, Inc. ("Heat") (NASDAQ: HTBX), a clinical-stage biopharmaceutical company focused on developing first-in-class therapies to modulate the immune system, today provided financial, clinical an
5y agoHTBXHeat Biologics Announces Groundbreaking for New San Antonio FacilityGlobeNewswireDURHAM, N.C., Aug. 09, 2021 (GLOBE NEWSWIRE) -- Heat Biologics, Inc. ("Heat") (NASDAQ: HTBX), a clinical-stage biopharmaceutical company focused on developing first-in-class therapies to modulate the immune system, today announced it will be hosting a
5y agoHTBXHeat Biologics Joins Russell Microcap® IndexGlobeNewswireDURHAM, N.C., June 28, 2021 (GLOBE NEWSWIRE) -- Heat Biologics, Inc. (NASDAQ:HTBX), a clinical-stage biopharmaceutical company focused on developing first-in-class therapies to modulate the immune system, today announced that it has been added to the R
5y agoHTBXHeat Biologics Announces Significant Expansion of R&D and Pre-Clinical Capabilities at Corporate HeadquartersGlobeNewswireDURHAM, N.C., June 23, 2021 (GLOBE NEWSWIRE) -- Heat Biologics, Inc. ("Heat") (NASDAQ: HTBX), a clinical-stage biopharmaceutical company focused on developing first-in-class therapies to modulate the immune system, including multiple oncology product c
5y agoHTBXHeat Biologics to Showcase Favorable Survival Data of HS-110 in Previously Treated Non-Small Cell Lung Cancer Patients at 2021 American Society of Clinical Oncology Annual MeetingGlobeNewswireDURHAM, N.C., June 04, 2021 (GLOBE NEWSWIRE) -- Heat Biologics, Inc. (NASDAQ:HTBX), a clinical-stage biopharmaceutical company focused on developing first-in-class therapies to modulate the immune system, today announced that Dr. Roger B. Cohen, MD, Pr
5y agoHTBXHeat Biologics Announces Promising Survival Data of HS-110 in Two Treatment Settings of Lung Cancer; Selected for Presentation at 2021 American Society of Clinical Oncology Annual MeetingGlobeNewswireDURHAM, N.C., May 20, 2021 (GLOBE NEWSWIRE) -- Heat Biologics, Inc. (NASDAQ:HTBX), a clinical-stage biopharmaceutical company focused on developing first-in-class therapies to modulate the immune system, today announced that the latest data from HS-110
5y agoHTBXHeat Biologics Announces Multiple Presentations on PTX-35 at the Upcoming 3rd Annual Treg Directed Therapies SummitGlobeNewswireDURHAM, N.C., May 19, 2021 (GLOBE NEWSWIRE) -- Heat Biologics, Inc. (NASDAQ:HTBX), a clinical-stage biopharmaceutical company focused on developing first-in-class therapies to modulate the immune system, today announced that PTX-35 will be featured in
5y agoHTBXHeat Biologics Appoints Anthony Manning, Ph.D. as Chief Scientific AdvisorGlobeNewswireDURHAM, N.C., May 10, 2021 (GLOBE NEWSWIRE) -- Heat Biologics, Inc. (NASDAQ:HTBX), a clinical-stage biopharmaceutical company focused on developing first-in-class therapies to modulate the immune system, including multiple oncology product candidates
5y agoHTBXHeat Biologics Provides First Quarter 2021 Business Update; Reports Continued Progress on Oncology and COVID-19 Vaccine ProgramsGlobeNewswireDURHAM, N.C., May 05, 2021 (GLOBE NEWSWIRE) -- Heat Biologics, Inc. ("Heat") (NASDAQ: HTBX), a clinical-stage biopharmaceutical company focused on developing first-in-class therapies to modulate the immune system, including multiple oncology product ca
5y agoHTBXHeat Biologics Announces New Preclinical Data on PTX-35, Demonstrating Decreased Regulatory T-cell (Treg) Activity and Delayed Tumor Progression at American Association for Cancer Research (AACR) Annual Meeting 2021ACCESS NewswireHeat Biologics, Inc. (NASDAQ:HTBX), a clinical-stage biopharmaceutical company focused on developing first-in-class therapies to modulate the immune system, including multiple oncology product candidates and a novel COVID-19 vaccine, today reported that promising new preclinical data of PTX-35 is presented at the AACR Annual Meeting 2021.
5y agoHTBXHeat Biologics Provides Year-End Business UpdateACCESS NewswireHeat Biologics, Inc. (NASDAQ:HTBX), a clinical-stage biopharmaceutical company focused on developing first-in-class therapies to modulate the immune system, including multiple oncology product candidates and a novel COVID-19 vaccine, today provided financial, clinical and operational updates for the year ended December 31, 2020.
5y agoHTBXHeat Biologics to Participate at M Vest LLC and Maxim Group LLC Inaugural Emerging Growth Virtual ConferenceACCESS NewswireHeat Biologics, Inc. (NASDAQ:HTBX), a clinical-stage biopharmaceutical company focused on developing first-in-class therapies to modulate the immune system, including multiple oncology product candidates and a novel COVID-19 vaccine, today announced that Jeff Wolf, CEO of Heat Biologics, has been invited to present at , hosted by M Vest LLC and Maxim Group LLC. The presentation will be available t ...
5y agoHTBXHeat Biologics to Present at 2021 BIO CEO & Investor Digital ConferenceACCESS NewswireHeat Biologics, Inc. ("Heat") (Nasdaq:HTBX), a clinical-stage biopharmaceutical company focused on developing first-in-class therapies to modulate the immune system, including multiple oncology product candidates and a novel COVID-19 vaccine, today announced that it will be presenting at the 2021 BIO CEO & Investor Digital Conference being held virtually between February 16-18, 2021.
5y agoKALV HTBX TYME ONTX+1Global Human Papillomavirus (HPV) Vaccine Market Could Exceed $12 Billion By 2027PR NewswireThe incidence of cancer is increasing every year and it has been the major factor for the growth of the cancer vaccines market. Healthcare physicians ...
5y agoHTBXHeat Biologics Announces Positive Interim Survival Data from Ongoing HS-110 Phase 2 Non-Small Cell Lung Cancer TrialACCESS NewswireMedian overall survival of 24.6 months in previously treated checkpoint inhibitor naïve non-small cell lung cancer patients who received HS-110 in combination with nivolumab
5y agoHTBXHeat Biologics Announces Publication of Additional Preclinical COVID-19 Vaccine ResultsACCESS NewswireSpike specific CD8+ and CD4+ T-cell memory responses observed 30- and 60- days post vaccination
5y agoHTBXHeat Biologics CEO to Participate in a Fireside Chat at the B. Riley Securities Oncology Investor Conference on Jan 21, 2021ACCESS NewswireHeat Biologics, Inc. ("Heat") (NASDAQ:HTBX), a clinical-stage biopharmaceutical company focused on developing first-in-class therapies to modulate the immune system, including multiple oncology product candidates and a novel COVID-19 vaccine, today announced that Jeff Wolf, Chief Executive Officer of Heat Biologics, will participate in a fireside chat at the B. Riley Securities Virtual Oncology In ...
5y agoHTBXHeat Biologics Commences Manufacturing Process for ZVX-60ACCESS NewswireHeat Biologics, Inc. ("Heat") (NASDAQ:HTBX), a clinical-stage biopharmaceutical company focused on developing first-in-class therapies to modulate the immune system, including multiple oncology product candidates and a novel COVID-19 vaccine, today announces it has transferred its gp96-based COVID-19 vaccine cell line ("ZVX-60") to Waisman Biomanufacturing to initiate the manufacturing process for ...
5y agoHTBXHeat Biologics Promotes William L. Ostrander to Chief Financial OfficerACCESS NewswireDURHAM, NC / ACCESSWIRE / January 11, 2021 / Heat Biologics, Inc. ("Heat") (NASDAQ:HTBX), a clinical-stage biopharmaceutical company focused on developing first-in-class therapies to modulate the immune system, including multiple oncology product candidates and a novel COVID-19 vaccine, today announces it has appointed William Ostrander as its Chief Financial Officer, effective January 4, 2021. Mr ...
5y agoHTBXNew patent application published for: Vector Co-Expressing Vaccine and Costimulatory MoleculesUS Patent Applications (USPTO)
5y agoCNSP SIOX HTBX BMY+1Glioblastoma Multiforme (GBM) Treatments Advancing as FDA Steps Up Measures Due to Rising IncidencesPR NewswireGlioblastoma multiforme (GBM) is the most common and aggressive malignant brain tumor in humans that involves glial cells. GBM is present in two...
5y agoHTBXHeat Biologics Announces Completion of ZVX-60 Vaccine Cell Line for COVID-19ACCESS NewswirePreparations for manufacturing underway
5y agoHTBXHeat Biologics Provides Business UpdateACCESS NewswireHeat Biologics, Inc. ("Heat") (NASDAQ:HTBX), a clinical-stage biopharmaceutical company focused on developing first-in-class therapies to modulate the immune system, including multiple oncology product candidates and a novel COVID-19 vaccine, today announced a planned reverse stock split of its shares of common stock at a ratio of 1-for-7. The reverse stock split will take effect as of 12:01 a.m. ...
5y agoHTBX VXRT IBIO DVAXNew Surge of Cases Emphasizes the Need for Widespread Diagnostic SolutionsPR NewswireNew restrictions are being implemented in several states across the country as the number of those infected with COVID-19 is once again on the rise....